Individualizing anaemia therapy

NDT Plus

Volumn 3, Issue 6, 2010, Pages 519-526

  De Francisco, Angel L M ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

anaemia; erythropoiesis stimulating agents; haemoglobin

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CARDIAC PATIENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HEART INFARCTION; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTRACARDIAC THROMBOSIS; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VASCULAR ACCESS;

EID: 78649476112     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfq164     Document Type: Review

References (79)

1. Finkelstein FO, Story K, Firanek C et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 33-38
2. Pisoni RL, Bragg-Gresham JL, Young EWet al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 94-111
3. Boudville NC, Djurdjev O, Macdougall IC et al. Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. Clin J Am Soc Nephrol 2009; 4: 1176-1182
4. Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int 2009; 75: 15-24
5. Cody J, Daly C, Campbell M et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005 CD003266
6. Cody J, Daly C, Campbell M et al. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients. Cochrane Database Syst Rev 2005 CD003895
7. Locatelli F, Aljama P, Barany P et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19: ii1-ii47
8. Renal Association and the Royal College of Physicians of London. Treatment of Adults and Children with Renal Failure-Standards and Audit Measures 2002 3rd edn. http://www.renal.org/Standards/standards.html (16 March 2009, date last accessed)
9. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47: S11-S145
10. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530
11. Pollock C, McMahon L. The CARI guidelines. Biochemical and haematological targets guidelines. Haemoglobin. Nephrology (Carl-ton) 2005; 10: S108-S115
12. Locatelli F, Covic A, Eckardt KU et al. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24: 348-354
13. Locatelli F, Aljama P, Canaud B et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study. Nephrol Dial Transplant 2010; 25: 2846-2850
14. Xue JL, St Peter WL, Ebben JP et al. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002; 40: 1153-1161
15. Silberberg J, Racine N, Barre P et al. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990; 6: 1-4
16. Ofsthun N, Labrecque J, Lacson E et al. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003; 63: 1908-1914
17. Rossert J, Levin A, Roger SD et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006; 47: 738-750
18. Furuland H, Linde T, Ahlmen J et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003; 18: 353-361
19. McMahon LP, Mason K, Skinner SL et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000; 15: 1425-1430
20. Eschbach JW, Aquiling T, Haley NR et al. The long-term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 1992; 38 Suppl 1: S98-S103
21. Jones M, Ibels L, Schenkel B et al. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 2004; 65: 757-767
22. Ma JZ, Ebben J, Xia H et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610-619 (Pubitemid 29117643)
23. Portoles J, Torralbo A, Martin P et al. Cardiovascular effects of re-combinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29: 541-548
24. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335
25. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189
26. Strippoli GF, Navaneethan SD, Craig JC. Haemoglobin and haemato-crit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2006: CD003967
27. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
28. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfain chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
29. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
30. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
31. Pfeffer MA, Eckardt KU, Toto R. Darbepoetin alfa and chronic kidney disease [author response]. N Engl J Med 2010; 362: 653-655
32. Macdougall IC, Eckardt KU, Locatelli F Latest US KDOQI Anaemia Guidelines update\what are the implications for Europe? Nephrol Dial Transplant 2007; 22: 2738-2742
33. Levin A. Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 2007; 22: 309-312
34. De Francisco AL, Aljama P, Arias M et al. Anaemia correction in diabetic patients with chronic kidney disease without substitutive treatment: teachings from TREAT study. Nefrologia 2010; 30: 15-20
35. Roger SD, Levin A. Epoetin trials: randomised controlled trials don't always mimic observational data. Nephrol Dial Transplant 2007; 22: 684-686
36. Prisant A. TREAT versus treatment: a patient's view of a scientific interpretation. Am J Kidney Dis 2010; 55: A31-A32
37. Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 3270-3277
38. Perez-Garcia R, Martin-Malo A, Fort J et al. Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER\a multicentre, prospective, observational cohort study. Nephrol Dial Transplant 2009; 24: 578-588
39. Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003; 41: 111-124
40. Rossert J, Gassmann-Mayer C, Frei D et al. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 2007; 22: 794-800
41. Kalantar-Zadeh K, Lee GH, Miller JE et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 2009; 53: 823-834
42. Brookhart MA, Schneeweiss S, Avorn J et al. The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol 2008; 19: 1389-1395
43. Locatelli F, Andrulli S, Memoli B et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 991-998
44. Kainz A, Mayer B, Kramar R et al. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 3701-3706
45. Brookhart MA, Schneeweiss S, Avorn J et al. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 2010; 303: 857-864
46. Zhang Y, Thamer M, Stefanik K et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876
47. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798
48. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191
49. Bradbury BD, Wang O, Critchlow CWet al. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 2008; 51: 62-70
50. Cotter DJ, Thamer M, Zhang Y. Relative mortality and epoetin alpha dose in hemodialysis patients. Am J Kidney Dis 2008; 51: 865 author reply 865-866
51. Zhang Y, Thamer M, Cotter D et al. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol 2009; 4: 638-644
52. Brunelli SM, Joffe MM, Israni RK et al. History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 777-782
53. Ebben JP, Gilbertson DT, Foley RN et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitali-zations. Clin J Am Soc Nephrol 2006; 1: 1205-1210
54. Yang W, Israni RK, Brunelli SM et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007; 18: 3164-3170
55. Minutolo R, Chiodini P, Cianciaruso B et al. Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 552-559
56. De Nicola L, Conte G, Chiodini P et al. Stability of target hemoglobin levels during the first year of epoetin treatment in patients with chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 938-946
57. Gilbertson DT, Ebben JP, Foley RN et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008; 3: 133-138
58. Agarwal R. Individualizing decision-making\resurrecting the doctor-patient relationship in the anemia debate. Clin J Am Soc Nephrol 2010; 5: 1340-1346
59. Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol 2008; 36: 1573-1584
60. Deicher R, Horl WH. Differentiating factors between erythropoiesis- stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs 2004; 64: 499-509
61. Macdougall IC, Robson R, Opatrna S et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 1211-1215
62. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68: 1337-1343
63. de Francisco AL, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT Plus 2009; 2: i18-i26
64. De Nicola L, Minutolo R, Conte G. Anaemia management in non-dialysis chronic kidney disease: flexibility of target to target stability? Nephron Clin Pract 2010; 114: c236-c241
65. Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol 2009; 20: 479-487
66. Singh AK, Milford E, Fishbane S et al. Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Kidney Int 2008; 74: 679-683
67. Yee J, Zasuwa G, Frinak S et al. Hemoglobin variability and hypor-esponsiveness: much ado about something or nothing?. Adv Chronic Kidney Dis 2009; 16: 83-93
68. Bonafont X, Bock A, Carter D et al. A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis. NDT Plus 2009; 2: 347-353
69. Yaqub MS, Leiser J, Molitoris BA. Erythropoietin requirements increase following hospitalization in end-stage renal disease patients. Am J Nephrol 2001; 21: 390-396
70. Kalantar-Zadeh K, McAllister CJ, Lehn RS et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42: 761-773
71. Schindler R, Boenisch O, Fischer C et al. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 2000; 53: 452-459
72. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1207-1211
73. Ayus JC, Mizani MR, Achinger SG et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005; 16: 2778-2788
74. Ramirez R, Carracedo J, Merino A et al. Microinflammation induces endothelial damage in hemodialysis patients: the role of convective transport. Kidney Int 2007; 72: 108-113
75. Fouque D, Kalantar-Zadeh K, Kopple J et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73: 391-398
76. Hayashi K, Hasegawa K, Kobayashi S. Effects of angiotensin-con-verting enzyme inhibitors on the treatment of anemia with erythro-poietin. Kidney Int 2001; 60: 1910-1916
77. Macdougall IC. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 1999; 14: 1836-1841
78. Singh AK. The controversy surrounding hemoglobin and erythropoi-esis- stimulating agents: what should we do now? Am J Kidney Dis 2008; 52: S5-S13
79. Eckardt KU, Kim J, Kronenberg F et al. Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol 2010 [Epub ahead of print]